09 January 2026
09 January 2026
The New Jersey pharma will now offer some of its branded medicines on the US government-created DTC platform, TrumpRx. gov.
Alveus will use the funds to support a Phase II trial and progress more assets towards the clinic.
Under the agreement, Santhera will receive an initial payment of $40m from Nxera.
Takeda will make an upfront payment to Halozyme in addition to commercial milestone payments.
The deal marks Lilly’s first in the M&A arena in 2026 as the company diversifies its pipeline beyond obesity drugs.
GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
